Change the world

J2HBiotech - Journey to Healthcare Solutions

History

img

  1. 2022

    1. MASH drug candidate (J2H-1702) entered phase 2 clinical trial
    2. New drug candidate for multiple sclerosis (J2H-1801) entered GLP Toxicity studies/NSCLC PROTAC drug candidate (J2H-2002) entered GLP Toxicity studies
    3. Pharmaceutical business division (Ansan) facility received kGMP certification
  2. 2021

    1. Clinical research team established
    2. Development of novel drug R&D platform technology PROTACTICS®
    3. Pharmaceutical business division established (Ansan)
  3. 2020

    1. MASH drug candidate (J2H-1702) entered phase 1 clinical trial
    2. Received Inno-Biz technology innovation small and medium enterprise certification/Designated as the excellent corporation R&D center (Ministry of Science and ICT)
    3. Established Fine chemicals division Asan facility
  4. 2019

    1. Selected as the Preliminary unicorn company (Ministry of SMEs and Startups)
    2. Development of R&D platform technology, OPTIFLEX®
  5. 2018

    1. J2H Tenofovir disoproxil approved by Korean Ministry of Food and Drug Safety
  6. 2017

    1. HQ relocated/Opened R&D center (Suwon venture valley II)
    2. Won patent lawsuit for the blockbuster generic against 11 pharmaceutical companies
  7. 2015

    1. Certified as a venture company (Korean venture capital association) & certified as Company affiliated research institute (Korea Industrial Technology Association)
  8. 2014

    1. Founding of J2H Biotech

History